Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
Sponsor: Novartis Pharmaceuticals
Summary
The purpose of this study is to continue to assess safety and tolerability, and to allow continued access to study treatment for subjects already receiving spartalizumab as single agent or in combination with other study treatments.
Official title: An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2019-10-30
Completion Date
2030-04-30
Last Updated
2025-10-07
Healthy Volunteers
No
Conditions
Interventions
PDR001
PDR001
Locations (48)
Columbia University Medical Center
New York, New York, United States
Providence Portland Medical Center
Portland, Oregon, United States
MD Anderson Cancer Center Uni of Te
Houston, Texas, United States
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Montreal, Quebec, Canada
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
High West, Hong Kong
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Pokfulam, Hong Kong
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Debrecen, Hungary
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Rozzano, MI, Italy
Novartis Investigative Site
Modena, MO, Italy
Novartis Investigative Site
Aviano, PN, Italy
Novartis Investigative Site
Siena, SI, Italy
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Leiden, South Holland, Netherlands
Novartis Investigative Site
Gdansk, Poland
Novartis Investigative Site
Poznan, Poland
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
L'Hospitalet de Llobregat, Barcelona, Spain
Novartis Investigative Site
Barcelona, Catalonia, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Zurich, Switzerland
Novartis Investigative Site
Taipei, Taiwan
Novartis Investigative Site
Songkhla, Hat Yai, Thailand
Novartis Investigative Site
Bangkok, Thailand
Novartis Investigative Site
Chiang Mai, Thailand